Wall Street Zen Upgrades Indivior (NASDAQ:INDV) to Strong-Buy

Indivior (NASDAQ:INDV) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Separately, Piper Sandler reduced their price objective on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Indivior has an average rating of “Buy” and an average target price of $15.00.

Indivior Price Performance

Shares of NASDAQ INDV opened at $14.01 on Friday. Indivior has a 1 year low of $7.33 and a 1 year high of $16.98. The stock has a market cap of $1.92 billion, a P/E ratio of -45.19 and a beta of 0.66. The firm has a 50-day moving average of $11.67 and a 200 day moving average of $11.04.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.19. The business had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. Research analysts expect that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

A number of large investors have recently made changes to their positions in INDV. VELA Investment Management LLC grew its stake in shares of Indivior by 45.5% in the fourth quarter. VELA Investment Management LLC now owns 179,659 shares of the company’s stock worth $2,264,000 after acquiring an additional 56,224 shares during the period. Clark Estates Inc. NY grew its stake in shares of Indivior by 1.3% in the fourth quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock worth $3,199,000 after acquiring an additional 3,300 shares during the period. Amundi grew its stake in shares of Indivior by 12.2% in the fourth quarter. Amundi now owns 174,434 shares of the company’s stock worth $2,109,000 after acquiring an additional 19,010 shares during the period. Kazazian Asset Management LLC purchased a new position in shares of Indivior in the fourth quarter worth approximately $1,706,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Indivior in the fourth quarter worth approximately $978,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.